T-VEC injections into melanoma lesions show significant response

2014 ASCO Annual Meeting

T-VEC injections into melanoma lesions show significant response rate

Listen now

Description

Prof Harrington talks to ecancertv at ASCO 2014 about a randomised phase III trial of talimogene laherparepvec (T-VEC) versus subcutaneous granulocyte-macrophage colony-stimulating factor (GM-CSF) for the treatment of unresected stage IIIB/C and IV melanoma.

More Episodes

See all »

Comment: PD-1 targeting MK-3475 gives long-term responses in melanoma

At ASCO 2014, Dr O'Day provides ecancertv with his expert opinion on the findings from a large phase I study of 411 patients with advanced melanoma which showed that the PD-1 targeting antibody MK-3475 yields long-term responses in a high percentage of patients.

Published 07/15/14

2014 ASCO Annual Meeting

Published 07/15/14

ASCO 2014 roundup

ecancer's Prof McVie provides a roundup of the main points of discussion from ASCO 2014.

Published 07/11/14